Since chemotherapeutic drugs kill tumour cells by first order kinetics (Frei, 1972; Skipper, 1965) it has been suggested that eradication of a neoplastic process, coincident with effective in vivo chemotherapy, requires a host immune response to residual viable tumour cells. Indirect support for this concept derives from the observations that lower, rather than higher doses of cyclophosphamide produce greater cure rates in certain rodent tumours, and that, alkylating agent therapy has been reported to be more effective against experimental tumours in intact compared to immunosuppressed hosts (Mathe et al., 1977; Mokyr et al., 1983; MoQre et al., 1973) .
We previously reported that cyclosporin A (CsA), the endecapeptide immunosuppressive antibiotic, was an effective modulator of multidrug resistance (Slater et al., 1986a,b) . We now describe our use of CsA to enhance the effect of VP-16, the topoisomerase II inhibitor, on survival of BDF/I mice with drug sensitive L1210 leukaemia and demonstrate its paradoxical production of anti-leukaemic immunity in long surviving host mice.
Methods
Groups of ten or more BDF/1 mice were inoculated intraperitoneally (ip) with 100,000 L1210 leukaemia cells, freshly harvested from leukaemia bearing stock DBA/2 mice (Simonsen, Gilroy, CA). Host mice were treated with sid, Bristol) 5 mg kg-', ip on days 1 and 3 alone or combined with CsA (Sandimmune, Sandoz). Two CsA regimens were employed, 2 and 10mgkg-', the former because it is lower than the 3-5mgkg-', daily intravenous CsA dose used in humans (Canafax et al., 1983) . Alternate groups of mice were treated with a high dose VP-16 regimen of 60 mg kg-', ip on day 1 after leukaemia inoculation without CsA. Since the mean survival of BDF/1 mice inoculated with 100,000 L1210 leukaemia cells is in the range of 9-12 days, 60-day surviving mice, produced by high dose VP-16 alone or combined low dose VP-16 and CsA, were rechallenged, ip, with 100,000 L1210 leukaemia cells. In experiments designed to test the requirement for the presence of L1210 cells for the initiation of immune protection, the mean survival of groups of mice pretreated with CsA alone (0mg kg-'), VP-16 alone (5 mg kg-') and combined VP-16 and CsA, 60 days prior to challenge with L1210 leukaemia was 10.8 ± 3.0, 10.8 ± 1.6, and 11.3 ± 2.0 days respectively, compared to an untreated mean survival of 10.3 ± 0.5 days.
In 0.8 days respectively). Whereas a survival plateau was observed in five of 11 mice that received the immune spleen cell -L1210 leukaemia admixture, P<0.0001 vs the nonimmune spleen cell -L1210 leukaemia control group. Figure  2b presents the pooled comparision of survival from three independent experiments of mice that received the immune spleen cell L1210 leukaemia admixture (n =26), P <0.0001 vs the non-immune spleen cell admixture (n = 49). Because these animals withstool leukaemia rechallenges on days 49 and 84 we compared the ability of their splenocytes to protect a subsequent cohort of normal BDF/1 recipient animals, when admixed in a ratio of 1000:1 with 10,000 L1210 leukaemia cells, i.e. spleen cells from animals that had previously received L1210 leukaemia plus immune spleen cells were used to protect naive recipients. Figure 3 shows perpetuation of the passive protective effect against L1210 leukaemia by these splenocytes vs control spleen cells, to three subsequent cohorts of recipient animals when splenocytes harvested from each preceding cohort are admixed with L1210 leukaemia, P<0.01, 0.0001 and 0.0001 respectively.
In order to determine if the production of leukaemia immunity in passively protected recipient mice requires the contribution of an autologous immune response, survival of cyclophosphamide pretreated animals was compared to survival of non-immunosuppressed control recipients in adoptive transfer experiments. Figure 4a shows no difference in survival between these groups. It should be noted, however, that there is striking difference in survival between a subsequent cohort of normal recipient animals inoculated with L1210 leukaemia admixed with splenocytes obtained from the non-immunosuppressed vs the previously cyclophosphamide immunosuppressed animals when they are used as splenocyte donors, Figure 4b, Goldin et al. originally reported the ability of long surviving mice, produced by successful treatment of L1210 leukaemia with amethopterin derivatives, to reject subsequent L1210 leukaemia challenge (Goldin et al., 1959) . It was not possible to adoptively transfer this immunity (Goldin et al., 1960) . Mihich subsequently succeeded in passive transfer of L1210 leukaemia immunity by pretreatment of normal mice 4 h prior to L1210 leukaemia challenge with splenocytes or lymph node cells, obtained from long surviving cytosine arabinoside-nitrosourea treated host animals (Mihich, 1969) . It is unclear if the explanation for these early observations relates to immune modulating effects of cytotoxic chemotherapy. Subsequent reports suggest this association, as both chemotherapeutic augmentation of immune effector cells and inhibition of tumour suppressor cells have been described (Barker & Mokyr, 1988; Berendt & North, 1980; North, 1982) . Cyclosporin A, the potent immunosuppressive antibiotic, cannot only promote organ survival in allotransplantation but also, paradoxically, break tolerance to self producing organ specific autoimmune disease in mice (Sakaguchi & Sakaguchi, 1988 (Glazier et al., 1983) . Syngeneic graft vs host disease developed after the withdrawal of chronic CsA therapy following marrow transplantation, and could be adoptively transferred to irradiated but not to normal syngeneic recipients. It was later shown that sGVHD is age and thymus dependent and that cytotoxic, autoreactive T splenocytes with polyclonal anti-Ia specificity and activity against a syngeneic Ia positive plasmacytoma could be harvested from rats undergoing the sGVHD reaction (Hess et al., 1985; Geller et al., 1989) . Reactivity was maximal at the onset of clinical sGVHD after withdrawal of CsA, and declined to baseline as sGVHD symptoms resolved (Geller et al., 1989) . Although our L1210 leukaemia cells demonstrate Ia antigenicity, as determined flow cytometrically using indirect immunofluorescent staining of Anti I-Ad (Becton-Dickinson) monoclonal antibody (unpublished observation), immune animals fail to display signs of sGVHD.
Our experiments also show that passively protected first cohort mice are immune to leukaemia rechallenge. Splenocytes harvested from these animals are capable of protecting a second cohort of naive recipient mice. Splenocytes from the second cohort protect a third cohort, and third cohort splenocytes, in turn protect a fourth group of naive recipient animals. These events may relate to proliferation of donor cells in syngeneic hosts or immunological recruitment and expansion of recipient responses. Strongly in favour of the latter possibility is our observation relating to cyclophosphamide pretreatment of adoptive transfer recipient mice. Cyclophosphamide pretreatment of adoptive transfer recipient mice abrogates the ability of their splenocytes to perpetuate passive protection in sequential adoptive transfer experiments. Although cyclophosphamide can inhibit antitumour immunity by ablating suppressor cells (Hess et al., 1980) our observations are inconsistent with such a possibility since survival of cyclophosphamide pretreated and nonpretreated adoptive transfer recipient animals are the same.
The pharmacologic concept that chemotherapeutic agents produce a constant precent tumour cell kill is well established (Frei, 1972; Skipper, 1965) and it is widely felt that the cure of an intact animal after effective chemotherapy relates to the host response. Our current observations are probably an example of this phenomenon, since both cytotoxic and immunologic enhancement are produced by VP-16/CsA interactions.
Experiments are in progress to determine the mechanism of CsA initiated immunity in L1210 leukaemia and the splenic cellular population(s) responsible for its adoptive transfer.
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